Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Greenlight Biosciences, Inc. manages a diverse portfolio with 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 7 distinct art units, indicating that the company's research and development efforts span a wide range of specialized biological and pharmaceutical fields. The prosecution is further decentralized by the involvement of 8 distinct examiners, meaning each pending action is being reviewed by a different official. This variety suggests that the company must navigate a broad array of examiner temperaments and departmental interpretations.
Examiner ANTHOPOLOS, PETER is identified as the busiest examiner, though they only hold 1 pending office action. This highlights the extreme distribution of the workload, where no single examiner has a dominant influence over the portfolio. For practitioners, this environment requires a highly adaptable strategy, as they must manage multiple examiner relationships and navigate the specific nuances of the various art units simultaneously. The lack of concentration in any single art unit or under any specific examiner necessitates a case-by-case approach to prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANTHOPOLOS, PETER | 1 | 57.4% | +58.8% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
| ARIETI, RUTH SOPHIA | 1 | 46.7% | +71.1% |
| ZHENG, LI | 1 | 83.6% | +12.9% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| TRAN, CHRISTINA L | 1 | 51.6% | +48.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | — |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | — |
| 17779257 | NUCLEIC ACID COMPOSITIONS | TINSLEY, BRENDAN THOMAS | — |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17478015 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS | ZHENG, LI | 70d overdue |
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | — |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | — |
| 17779257 | NUCLEIC ACID COMPOSITIONS | TINSLEY, BRENDAN THOMAS | — |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
| 17202029 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17161641 | COMPOSITIONS AND METHODS FOR CONTROLLING ARTHROPOD PARASITE AND PEST INFESTATIONS | TRAN, CHRISTINA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1611 | 1 |
| 1636 | 1 |
| 1634 | 1 |
| 1635 | 1 |
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726667 | STABLE FORMULATIONS OF LIPID-ENCAPSULATED RNA | ANTHOPOLOS, PETER | 1611 | §102§103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18137022 | METHODS AND COMPOSITIONS FOR CONTROL OF ARTHROPOD PESTS | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 17779257 | NUCLEIC ACID COMPOSITIONS | TINSLEY, BRENDAN THOMAS | 1634 | §102§112 | Non-Final OA | — | Pending | May 24, 2022 |
| 17734703 | MESSENGER RNA THERAPEUTICS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Final Rejection | — | Pending | May 02, 2022 |
| 17478015 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS | ZHENG, LI | 1662 | §112 | Non-Final OA | 70d overdue | Pending | Sep 17, 2021 |
| 17202029 | CELL-FREE PRODUCTION OF RIBONUCLEIC ACID | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | DP | Non-Final OA | — | Pending | Mar 15, 2021 |
| 17161641 | COMPOSITIONS AND METHODS FOR CONTROLLING ARTHROPOD PARASITE AND PEST INFESTATIONS | TRAN, CHRISTINA L | 1637 | DPOther | Non-Final OA | — | Pending | Jan 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial